Masimo Stock Is Stuck Just Below Danaher’s $180 Bid. The Gap Is the Story
Masimo shares traded at $178.78 before Thursday’s open, just below Danaher’s $180-a-share cash offer, as investors
Brighthouse Financial Stock Carries $70 Cash Tag, But Market Holds Back
Brighthouse Financial last traded at $62.40, 11% below Aquarian Capital’s $70-per-share cash offer. No new merger vote appeared in recent SEC filings, which listed only standard annual-meeting items. The deal’s spread reflects
Spero Stock Falls With Two Weeks Left Until FDA Decision
Spero Therapeutics shares fell 1.1% to $2.80 Wednesday, underperforming the SPDR S&P Biotech ETF’s 1.5% gain. The FDA is set to decide by June 18 on tebipenem HBr, Spero’s oral antibiotic for complicated urinary tract infections, developed with GSK. Spero ended March with $56.1 million in cash and expects funding to last into 2028.
Pacira Stock Waits for June 9 Board Fight
ISS and Glass Lewis both backed Pacira BioSciences’ board slate ahead of the June 9 proxy vote, rejecting DOMA Perpetual Capital Management’s nominees. Pacira shares closed at $22.33, up 8 cents, with a market cap near $914 million. First-quarter revenue rose 5% to $177.4 million. Pacira reaffirmed its 2026 revenue guidance and 5x30 growth plan.
G-III Shares Trade Lower Ahead of Results, Marc Jacobs a Focus
G-III Apparel Group shares fell nearly 1% to $32.26 Wednesday as investors awaited first-quarter fiscal 2027 earnings and updates on portfolio changes. The company projects a $470 million sales drop from losing Calvin Klein and Tommy Hilfiger licenses, with first-quarter sales estimated at $530 million, down from $583.6 million last year. G-III plans to invest about $500 million in a new Marc Jacobs joint venture.
Lite Strategy Stock Faces Litecoin Setback
Lite Strategy Inc shares rose 1.7% to $0.83 in midday U.S. trading Wednesday as Litecoin, its core reserve asset, slipped 1.5% to $47.47. The company reported a quarterly net loss of $23.7 million, including an $18.8 million hit from digital asset revaluation. Trading volume reached about 349,000 shares. Lite Strategy’s treasury net asset value per share stood at $1.23.
Kyverna Therapeutics Stock Barely Moves—The Bigger CAR-T Test Is Coming
Kyverna Therapeutics shares were little changed at $7.90 after updated Phase 1 data showed four of six rheumatoid arthritis patients met ACR70 at 36 weeks with no severe immune or neurological side effects. The Phase 2 trial comparing miv-cel to rituximab is fully enrolled. Kyverna began a rolling BLA for miv-cel in stiff person syndrome and reported $236.4 million in cash as of March 31.
Telesat Shares Drop Ahead of AGM With Lightspeed Concerns Returning
Telesat shares fell 5.1% to $47.57 early Wednesday on Nasdaq ahead of the company’s annual shareholder meeting. First-quarter revenue dropped 25% to C$87 million, with a net loss widening to C$151 million. Telesat has invested about C$2.7 billion in its Lightspeed LEO satellite project and aims for global service by early 2028. Competition from Starlink and Amazon remains a key concern for investors.
Kodiak AI Stock Barely Moves, But One $6.50 Number Is Still Steering the Trade
Kodiak AI shares slipped 2 cents to $6.96 Wednesday, trading near the $6.50 price from its recent $100 million private share sale. The company reported first-quarter revenue of $1.8 million and negative free cash flow of $35 million, ending March with $90.2 million in cash. Investors remain focused on Kodiak’s capital needs and scaling plans despite a new workplace award. Aurora Innovation shares also traded lower.
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet
Mineralys Therapeutics shares dropped 8.7% premarket after the company priced a $150 million stock offering at $26.50 a share to fund a $200 million royalty buyout with Tanabe Pharma. The company also secured a five-year, $500 million term loan from Pharmakon Advisors. Lorundrostat, its lead hypertension drug, is under FDA review with a decision expected by December 2026. AstraZeneca’s rival drug Baxfendy was approved in May.
Telesat Shares Drop Ahead of AGM With Lightspeed Concerns Returning
Telesat shares fell 5.1% to $47.57 early Wednesday on Nasdaq ahead of the company’s annual shareholder meeting. First-quarter revenue dropped 25% to C$87 million, with a net loss widening to C$151 million. Telesat has invested about C$2.7 billion in its Lightspeed LEO satellite project and aims for global service by early 2028. Competition from Starlink and Amazon remains a key concern for investors.
Kodiak AI Stock Barely Moves, But One $6.50 Number Is Still Steering the Trade
Kodiak AI shares slipped 2 cents to $6.96 Wednesday, trading near the $6.50 price from its recent $100 million private share sale. The company reported first-quarter revenue of $1.8 million and negative free cash flow of $35 million, ending March with $90.2 million in cash. Investors remain focused on Kodiak’s capital needs and scaling plans despite a new workplace award. Aurora Innovation shares also traded lower.
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet
Mineralys Therapeutics shares dropped 8.7% premarket after the company priced a $150 million stock offering at $26.50 a share to fund a $200 million royalty buyout with Tanabe Pharma. The company also secured a five-year, $500 million term loan from Pharmakon Advisors. Lorundrostat, its lead hypertension drug, is under FDA review with a decision expected by December 2026. AstraZeneca’s rival drug Baxfendy was approved in May.
Opendoor Gets Russell Push, Key Test Nears
Opendoor Technologies shares traded near $5.37 in premarket Wednesday, down from Tuesday’s $5.41 close, after heavy volume driven by its upcoming Russell 3000 inclusion set for June 26. CEO Kaz Nejatian is urging shareholders to vote before the June 11 annual meeting, as proxy advisors recommended voting against his board seat. First-quarter revenue fell to $720 million, with a net loss of $173 million.
EOSE Stock Climbs Before Crucial Share Vote as Eos Energy Bulls Eye Grid-Storage Funding
Eos Energy Enterprises shares closed up 4.8% at $9.42 Tuesday, ahead of its annual meeting where investors will vote on raising authorized common stock to 800 million shares from 600 million. The company said only 7% of authorized shares remain available. Alessandro Lagi is set to become CFO on June 8. Trading volume reached about 26.4 million shares.
Liberty Broadband Slides; Market Focuses on Charter Deal Figure
Liberty Broadband Class C shares fell 0.9% to $33.13 at midday, closely tracking Charter Communications’ stock. The price is just below Charter’s all-stock offer, now valuing Liberty at $33.38 per share. No new updates have been posted by Liberty since a May 15 preferred dividend notice. Charter’s planned acquisition of Liberty remains on the original terms.
Warner Bros. Discovery Faces $31 Merger Bar as Regulators Step In
Warner Bros. Discovery closed at $26.97 on Thursday, 13% below Paramount Skydance’s $31-a-share cash offer. Investors are awaiting a European Commission antitrust decision due by July 7. WBD shareholders have approved the $110 billion sale. Paramount’s legal team says regulatory reviews are standard and filings are in with authorities in Europe, Canada, the UK, and the US.
NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment
NewcelX Ltd. shares edged up 0.6% to $3.18 in midday Nasdaq trading Thursday as investors awaited a late-June FDA meeting on its stem cell therapy for type 1 diabetes. The company submitted pre-IND materials for NCEL-101 and ended 2025 with $2.2 million in cash after an $8.3 million net loss.
Ohmyhome Shares Tick Higher, Investors Keep Focus on Burn Rate
Ohmyhome Limited shares rose 1.25% to $0.7189 on Nasdaq Thursday, trading at micro-cap levels with a market cap near $17.3 million. The Singapore proptech firm reported a 2025 net loss of S$9.2 million, up from S$4.4 million last year, and warned of ongoing negative cash flow. Brokerage revenue fell 32.6% while property management grew. Trading remained thin as investors eyed liquidity risks.
Bank7 Stock Climbs as 27-Cent Dividend Lands: What BSVN Investors Need to Know
Bank7 Corp shares rose 1.2% to $43.67 in thin Nasdaq trading Thursday as the company maintained its quarterly dividend at 27 cents a share, payable July 7 to holders as of June 19. First-quarter net income climbed 16.2% to $12.01 million, with total loans up 11.9% to $1.59 billion. The bank’s risk-based capital ratio stood at 15.96% on March 31. Bank7 warned that economic shifts could affect rates, credit quality, and loan demand.
Shuttle Pharma Drops After Dogecoin Move Gets First Look From Investors
Shuttle Pharmaceuticals shares fell 3.2% to $0.507 after the company shifted from cancer-drug development to mining Dogecoin and Litecoin. The firm completed its merger with United Dogecoin and announced a $9.55 million private placement. Shuttle reported no revenue and a $2.2 million net loss for the last quarter, with a working-capital deficit near $5.8 million. Crypto mining stocks and Dogecoin also declined.
ICON Stock Jumps Again After Accounting Cloud Clears, One Risk Lingers
ICON plc shares rose 5.1% to $151.21 in New York after closing an accounting probe and restating revenue, which was overstated by 0.8% in 2023 and 1.1% in 2024. The company reported Q4 revenue of $2.11 billion and set 2026 revenue guidance below 2025 levels. Analysts raised price targets, and two new board members joined. ICON flagged ongoing material weaknesses in internal controls.
Decent Holding Shares Pop Again As DXST Keeps Up Volatile Week
Decent Holding Inc. surged 18.1% to $5.67 on Nasdaq after reporting about $8 million in preliminary revenue and adding 387 elderly-care sites in China from January to May. Chairman Dingxin Sun recently bought 400,000 Class B shares, raising his voting power to 90.5%. Nearly 1.58 million shares traded. The stock’s jump contrasted with declines in broader tech and waste-services sectors.
Progyny Rises Again as Wall Street Keeps Buying Fertility-Benefits Rebound
Progyny Inc. shares climbed 3.4% to $25.83 Thursday morning after analyst upgrades and steady demand. The company reported record Q1 revenue of $328.5 million and net income of $24.2 million, despite losing a major client last year. Progyny announced a $200 million share buyback on May 26. The firm expects 2026 revenue between $1.365 billion and $1.405 billion.
Boost Run Shares Fall After Filing Shows Growth, Spending Plans
Boost Run shares fell 9.9% to $34.33 in early Nasdaq trading Thursday after the AI-infrastructure company released new guidance and quarterly results. Q1 revenue jumped 165% to $10.96 million, but net loss widened to $4.12 million. Annual recurring revenue reached $96 million as of April 30, with a $360 million contracted backlog. The company recently signed a $471.7 million, 36-month deal with Thinking Machines Lab.
Eikon Therapeutics Jumps Ahead of Biotech Peers
Eikon Therapeutics shares rose 5.1% to $9.91 late Thursday morning, still about 45% below the $18 IPO price from February. The company completed enrollment for its Phase 2 lung cancer trial, reporting a 63.1% objective response rate. Eikon ended Q1 with $596 million in cash but posted an $83 million loss. Analyst price targets averaged $24.80, with most maintaining a “Buy” rating.
IPOD Stock Is Flat—Why Collective Acquisition’s New CCAQ Tape Still Matters
Collective Acquisition Corp traded flat at $10.40 in thin Nasdaq action Thursday, with just 27 shares changing hands by 10:04 a.m. EDT. The SPAC held $149.2 million in trust at March 31 and reported no operating revenue. Shares hovered just above the $10.38 redemption value as investors awaited news on a potential deal.
GreenPower Stock Slips as Tiny EV Bus Maker Faces a Real-World Test
GreenPower Motor shares fell 0.89% to $1.11 in early Nasdaq trading Thursday, near the low end of a $1.10–$1.14 range, with no new order news. The company’s latest press release was a May 21 update on a heating system for its Nano BEAST bus. GreenPower’s market cap stood at about $5.5 million. Broader markets were mixed, with QQQ down 1.3% and Russell 2000 up 0.3%.
PolyPid Stock Barely Moves After FDA Filing, But a 2027 Decision Now Looms
PolyPid Ltd. shares rose 0.4% to $4.74 Thursday after the company completed its U.S. New Drug Application for D-PLEX100, an infection-prevention drug for colorectal surgery. The FDA is expected to decide on approval in early 2027. The filing is based on a Phase 3 trial showing a 60% reduction in surgical site infections versus standard care. PolyPid reported $10.9 million in cash at the end of March and a first-quarter net loss of $7.7 million.
Quest Resource edges higher, focus turns to June vote
Quest Resource Holding Corp. shares rose 0.7% to $1.38 Thursday on light volume after new proxy filings highlighted potential dilution and board elections ahead of its June 30 annual meeting. First-quarter revenue fell 9.8% to $61.7 million, while net loss narrowed to $2.3 million. Director Audrey Dunning received 2,966 RSUs at $1.18 each, vesting in 2027. Notes payable stood at $63.4 million as of March 31.
Perdoceo Stock Pops While Nasdaq Slips: What Investors Are Watching Now
Perdoceo Education shares rose 2.6% to $33.94 in early Nasdaq trading Thursday, outperforming a weaker tech sector. The move followed attention to its May earnings beat, a June 12 dividend, and a 2026 profit forecast of $3.05–$3.16 per share. First-quarter revenue rose 4.1% to $221.7 million, with enrollment up 1.1% to 48,740. Risks remain tied to student aid rules and for-profit education regulation.
Masimo Stock Is Stuck Just Below Danaher’s $180 Bid. The Gap Is the Story
Masimo shares traded at $178.78 before Thursday’s open, just below Danaher’s $180-a-share cash offer, as investors awaited regulatory clearance to close the $9.9 billion takeover. Shareholders approved the sale in May. The deal spread narrowed to about 0.7%. Nasdaq futures fell, but Masimo’s price tracked the pending merger rather than the broader market.
TPG Slides as Private Market Exit Fears Drag on Blackstone, KKR
TPG Inc shares fell 4.1% to $40.63 in premarket Nasdaq trading after Partners Group capped withdrawals from a key private-equity fund. Partners Group limited redemptions as requests topped its 5% quarterly limit, citing mounting pressure and warning of slower fundraising ahead. KKR and Blackstone shares also dropped about 4%. Investors are watching for broader stress in private equity and wealth products.
HeartSciences Stock Near $2: Why HSCS Traders Are Watching the AI-ECG Marketplace Launch
Steakholder Foods’ Nasdaq-listed ADSs fell 8 cents to $1.31 in premarket trading Wednesday, hovering just above the price used in its latest $1.1 million warrant exercise. The company could raise another $2.2 million if new warrants are exercised. Steakholder plans to launch its Perfecta plant-based meat in the U.S. in the second half of 2026.
Artesian Resources Stock Takes a Hit Before the Bell as One Delaware Decision Looms
Artesian Resources shares fell 1.7% to $32.06 before Thursday’s U.S. session, despite no new company news. The Delaware water utility last reported first-quarter revenue up 7.3% and a dividend increase. Artesian is seeking higher rates from state regulators, with two temporary hikes already in effect. Broader water stocks were mixed, suggesting Artesian’s drop was company-specific.
Steakholder Foods Shares Dip Toward Warrant Level as Investors Look at Cash Situation
Steakholder Foods’ ADSs closed at $1.31 in premarket trading, down 8 cents. The company disclosed a $1.1 million warrant exercise at $1.25 per share and said another $2.2 million could follow if more warrants are exercised. Steakholder reported no revenue for 2025 and an $11.25 million net loss. Its U.S. launch of Perfecta plant-based meat is planned for late 2026.